• Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Professional relationships and financial support, applicable to healthcare professionals and specialists
    • Relationships with and financial support from companies
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • Interruption or discontinuation of the supply of medical devices
    • New regulations
    • New Tech – new technological possibilities and medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
  • About us
    • Mission, vision and strategy
    • Contact
    • Organisation
    • Data Analytics Centre (DAC)
    • Whistleblowing scheme of the Danish Medicines Agency
    • The Danish Medicines Agency funding
    • Management of conflicts of interest
    • Transparency in the Danish Medicines Agency
    • Data protection policy
    • Targets and tasks
    • International collaboration
    • Jobs
    • Digital services
    • About this site
    • Social media
    • Design
    • Campaigns
    • Copyright and logo
    • Cookies
    • Publications
    • Sitemap
  • News
    • Subscribe to news
    • Edit subscription
    • Unsubscribe
    • News categories
    • Themes
    • RSS Feed
  • Publications
    • Order publications
    • 2025
    • 2024
    • 2023
    • 2022
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
Go to main content
  • News
  • About us
  • Contact us
  • Publications
  • Cookies
  • Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Professional relationships and financial support, applicable to healthcare professionals and specialists
    • Relationships with and financial support from companies
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • Interruption or discontinuation of the supply of medical devices
    • New regulations
    • New Tech – new technological possibilities and medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
2017
News / 2017
News

You must accept marketing cookies to share the page by mail

Update consent

Share by mail

Verify you are a human

...

  • GCP inspection updates

    Please note that the GCP inspection has updated information provided on the website.  The updates vary in scope, but texts have been adapted to Regulation (EU) no 536/2014 and Guideline ICH E6 R3

  • Deadline for pre-Christmas issue of export certificates for medicinal products: 12 December 2025

    Applications for export certificates for medicinal products must be received by 12 December 2025 to allow for review and issuance before Christmas.

  • Application deadlines for the issuance of import/export certificates for euphoriant substances before Christmas

    Applications for import/export certificates received via NDS Web must reach us by 16 December 2025 for review before Christmas. Applications submitted by any other means must reach us by 9 December 2025 for review before Christmas.

  • Deadline for receipt of applications for company authorisations: 15 December 2025

    Applications for company authorisations must reach us by 15 December 2025 for the review to begin before Christmas.

  • Bevilling til Brædstrup Apotek

    Lægemiddelstyrelsen har den 12. september 2018 meddelt Kerly Maire Servilieri bevilling til at drive Brædstrup Apotek.

  • Danish Medicines Agency shortens the review time for applications for COVID-19 medicine trials

    Drug regulatory authorities around the world are taking several steps to speed up the development and availability of medicines to treat and prevent novel COVID-19. The Danish Medicines Agency in Denmark has just implemented an emergency procedure for applications for clinical trials with human subjects.

  • EMA: No evidence linking ibuprofen to worsening of COVID-19

    The press and social media have raised questions about whether ibuprofen could worsen the condition of patients infected with COVID-19. The European Medicines Agency reports that there is currently no scientific evidence to suggest this. The Data Analytics Center of the Danish Medicines Agency now launches an ultra-quick study.

  • Henstilling om, hvordan præparatet remdesivir skal bruges til behandling af COVID-19 i såkaldt compassionate use-programs i EU

    Under et ekstraordinært møde, der blev afholdt den 2. april 2020, gav det europæiske medicinalagentur EMA's humane lægemiddeludvalg (CHMP) henstillinger om, hvordan præparatet remdesivir skal bruges til behandling af COVID-19 i såkaldt compassionate use-programs i EU, dvs. via udleveringstilladelser.

  • COVID-19: Restriction on OTC medicines lifted

    The Danish Medicines Agency lifts the restriction on over-the-counter (OTC), which has been in force since March. This means that pharmacies, supermarkets, kiosks and others with permission to sell OTC medicines can resume selling more than one pack of the same type of OTC medicine per customer.

  • Paracetamol til børn kan fremover midlertidigt kun købes på apoteker

  • EMA recommends conditional authorisation of the COVID-19 vaccine from Moderna

    The European Medicines Agency, EMA, has recommended the European Commission to grant a conditional authorisation for the COVID-19 vaccine for use throughout the European Union, including Denmark.

  • European Commission authorises one more COVID-19 vaccine

    On 6 January 2021, the European Commission granted a conditional marketing authorisation for the COVID-19 vaccine from Moderna. The vaccine has demonstrated a 94 per cent efficacy in trials. The authorisation is valid throughout the European Union including Denmark.

  • Thomas Senderovitz leaves the Danish Medicines Agency

    Thomas Senderovitz has announced that he is leaving his role as Director General of the Danish Medicines Agency to pursue fresh opportunities.

  • Publication of educational materials for centrally authorised medicinal products

    From January 1st 2023 and forward – and not retroactively – the Danish Medicines Agency now publishes educational material for medicinal products approved via the centralised procedure.

  • Registration of approved pack sizes in the Union Product Database

    In accordance with Commission Implementing Regulation (EU) 2021/16 of 8 January 2021, approved pack sizes for veterinary medicinal products must be registered in the Union Product Database (UPD). In connection with the registration of data in UPD, the Danish Medicines Agency has found that information on approved pack sizes in the summary of prouct characteristics (SPC) for veterinary medicinal products is not always complete. Therefore there may be missing information on approved pack sizes in the UPD for some products. Consequently, marketing authorisation holders (MAH) for veterinary medicinal products are encouraged to check the information in the UPD.

  • Union Product Database: Deadlines for the Submission of Annual Volume of Sales data for veterinary medicinal products

    According to Article 58(12) of Regulation (EU) 2019/6 , all Marketing Authorisation Holders must submit the annual Volume of Sales for each veterinary medicinal product to the Union Product Datab

  • New EU rules on falsified medicines

    When new EU rules enter into force on 9 February 2019, it will be harder for falsified medicines to reach patients in the EU. The new rules, which introduce new safety features on the packaging of medicines and other measures, are to prevent falsified medicines from entering the legal supply chain of medicines – for example in pharmacies and hospitals.

  • New report: Evaluation of the relationship reform

    The framework for collaboration between healthcare professionals and companies has just been evaluated. The evaluation concluded that the rules and administration work well, but compliance with the rules lags behind. There is a need for more information to healthcare professionals about the rules.

  • Danish Medicines Agency to send safety information directly to healthcare professionals

    When side effects or the like is discovered for medicines, the medicine’s product information sometimes needs to be changed to the point that healthcare professionals must be informed directly. Up to

  • Updating of summaries of product characteristics due to changed ATC codes for 2022

    Marketing authorisation holders of medicinal products authorised under the national procedure, the decentralised procedure as well as the mutual recognition procedure should be aware that some ATC codes have been changed for 2022.

  • Previous
  • 1
  • …
  • 21
  • 22
  • 23
  • Next
All items (450)
  • Time

    • 2025 (24)
    • 2024 (26)
    • 2023 (24)
    • 2022 (20)
    • 2021 (44)
    • 2020 (62)
    • 2019 (20)
    • 2018 (37)
    • 2017 (48)
    • 2016 (43)
    • 2013 (3)
    • 2012 (11)
    • 2011 (13)
    • 2010 (9)
    • 2009 (14)
    • 2008 (7)
    • 2007 (3)
    • 2006 (10)
footer-logo

Danish Medicines Agency

Axel Heides Gade 1

2300 København S

Email: dkma@dkma.dk


The Danish Medicines Agency is part of the
Ministry of Interior and Health.

Contact the Danish Medicines Agency

+45 44 88 95 95 (9am - 3pm)

Follow us

  • facebook logo
  • LinkedIn
  • RSS

CVR-nr. 37 05 24 85

EAN 5798 000 36 33 66

Privacy policy Cookie policy